Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, announced its participation in two investor conferences in September 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, announced its participation in two investor conferences in September 2021. The Morgan Stanley 19th Annual Global Healthcare Conference will feature a fireside chat with CEO Steven Nichtberger on September 9, while the H.C. Wainwright 23rd Annual Global Investment Conference will include a pre-recorded chat available on September 13. Both presentations will be accessible on Cabaletta's website for 90 days. The company focuses on engineered T cell therapies for B cell-mediated autoimmune diseases, with its lead candidate DSG3-CAART in Phase 1 trials.
Details
News Market Reaction – CABA
The recorded move for CABA in the trading session of this news was +1.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September:
- Morgan Stanley 19th Annual Global Healthcare Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, September 9, 2021 at 1:15 p.m. ET. Members of management will also be available for one-on-one meetings.
- H.C. Wainwright 23rd Annual Global Investment Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a pre-recorded fireside chat, which will become available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. ET. Members of management will also be available for one-on-one meetings.
Both presentations will be available on the News and Events section of the company’s website at www.cabalettabio.com. Replays will be available on the website for 90 days.
About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta’s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website (DesCAARTes™ Phase 1 Trial). The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.